ENHERTU Plus Pertuzumab Granted U.S. Breakthrough Therapy Status for HER2+ Metastatic Breast Cancer
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to ENHERTU (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab for the…
Read More...
Read More...
